Clinical trial NCT01732445: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Official title: A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anemia
Primary Myelofibrosis
Secondary Myelofibrosis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2012-11-22
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the efficacy (best overall response) of ruxolitinib (ruxolitinib phosphate) and danazol in patients with myelofibrosis suffering from anemia.

SECONDARY OBJECTIVES:

I. To evaluate the overall survival of patients with myelofibrosis suffering from anemia initiating ruxolitinib and danazol.

II. To evaluate the adverse event profile of ruxolitinib and danazol in patients with myelofibrosis suffering from anemia.

TERTIARY OBJECTIVES:

I. To evaluate quality of life (QOL) and patient-reported symptoms using the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) with ruxolitinib and danazol for patients with myelofibrosis suffering from anemia.

OUTLINE:

Patients receive ruxolitinib phosphate orally (PO) twice daily (BID) and danazol PO thrice daily (TID) on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.

After completion of study treatment, patients are followed up every 6 months for 2 years.

Eligibility criteria: Inclusion Criteria:

* Histological confirmation of primary myelofibrosis (MF), post polycythemia vera (PV) or post essential thrombocythemia (ET) myelofibrosis (intermediate 1, intermediate II or high risk) requiring medical therapy
* Anemia is required for trial entry (defined as hemoglobin \< 10g/dL or transfusion dependent \[having needed a transfusion anytime in the past 6 months\])
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at study entry
* Absolute neutrophil count (ANC) \>= 1000/uL
* Platelet count \>= 50,000/uL
* Serum creatinine =\< 1.5 x the upper limit of normal (ULN)
* Total bilirubin =\< 1.5 x ULN; if total bilirubin is \> 1.5 x ULN, a direct bilirubin should be performed and must be \< 1.5mg/dL
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN; higher values (i.e., =\< 5 x ULN) are allowed if clinically compatible with hepatic extramedullary hematopoiesis
* Life expectancy of \>= 6 months
* Patient able to provide voluntary written informed consent to participate
* Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study-related procedures
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only

Exclusion Criteria:

* Any chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide, interferon-alpha), immunosuppressive therapy, corticosteroids \> 10 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin), hormones (e.g., androgens, danazol) =\< 14 days prior to registration; note: patients who are on ruxolitinib may continue on without a 14 day wash out at the treating physician's discretion
* Major surgery =\< 28 days or radiation =\< 6 months prior to registration
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Active acute infection requiring antibiotics
* Uncontrolled congestive heart failure (New York Heart Association classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass, graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to registration
* Participation in any study of an investigational agent (drug, biologic, device) =\< 30 days, unless during non-treatment phase
* Any of the following:

  * Pregnant women
  * Nursing women
  * Men or women of childbearing potential who are unwilling to employ adequate contraception
* Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness
* Clinically active hepatitis B or C
* Active malignancy other than MF, except adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, cervical carcinoma in situ or other malignancies that have been stable and off therapy for 5 years
* Patient currently taking simvastatin, or lovastatin at a dose greater than 10 mg/day
* Men with prostate specific antigen (PSA) \> 4 ng/ml or with uncontrolled benign prostatic hypertrophy
* Patient received prior combination treatment with ruxolitinib and danazol together; note: previous treatment with ruxolitinib and/or danazol as single agent therapy is allowed
* Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of the following strong or moderate inhibitors are prohibited =\< 7 days prior to registration

  * Strong inhibitors of CYP3A4:

    * Indinavir (Crixivan)
    * Nelfinavir (Viracept)
    * Atazanavir (Reyataz)
    * Clarithromycin (Biaxin, Biaxin XL)
    * Itraconazole (Sporanox)
    * Ketoconazole (Nizoral)
    * Nefazodone (Serzone)
    * Saquinavir (Fortovase, Invirase)
    * Telithromycin (Ketek)
  * Moderate inhibitors of CYP3A4

    * Erythromycin (Erythrocin, E.E.S., Ery-Tab, Eryc, EryPed, PCE)
    * Fluconazole (Diflucan)
    * Grapefruit juice
    * Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan)
    * Verelan PM
    * Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)

Primary outcomes:
measure: Best Overall Response Rate as Determined by International Working Group Criteria
timeFrame: Up to 2 years
Secondary outcomes:
measure: Survival Time
timeFrame: From registration to death due to any cause, assessed up to 2 years
measure: Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)
timeFrame: Up to 2 years
Other outcomes:
measure: Patient-reported Symptoms Assessed Using the MPN-SAF, as Measured by the Percentage of Patients With a Decrease in MPN-SAF TSS Greater Than 50% From Baseline
timeFrame: Baseline to up to 2 years
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: New York
country: United States
facility: Tisch Cancer Center
state: New York
Study officials:
affiliation: Mayo Clinic
name: Ruben Mesa
role: PRINCIPAL_INVESTIGATOR
References: